Veru Net Income Per Share Over Time
| VERU Stock | USD 0.71 0.02 2.74% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Veru Performance and Veru Correlation. Veru |
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veru. If investors know Veru will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veru listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.30) | Revenue Per Share 0.117 | Quarterly Revenue Growth 0.183 | Return On Assets (0.64) | Return On Equity (1.27) |
The market value of Veru Inc is measured differently than its book value, which is the value of Veru that is recorded on the company's balance sheet. Investors also form their own opinion of Veru's value that differs from its market value or its book value, called intrinsic value, which is Veru's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veru's market value can be influenced by many factors that don't directly affect Veru's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veru's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veru is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veru's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Per Share Analysis
Compare Veru Inc and related stocks such as Seres Therapeutics, Protalix Biotherapeutics, and Lexicon Pharmaceuticals Net Income Per Share Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCRB | (0.1511) | (0.1511) | (0.1511) | (0.2049) | (0.5611) | (2.3279) | (2.2983) | (2.2097) | (2.4284) | (1.1341) | (1.0835) | (0.6706) | (2.3485) | (0.8884) | (0.93) |
| PLX | 0.6083 | (0.4316) | (0.1279) | (0.3009) | (0.3223) | 0.6114 | (0.2896) | (6.5054) | (1.7981) | (1.7685) | (0.5109) | (0.7699) | (0.3079) | 0.1231 | 0.13 |
| LXRX | (3.567) | (2.3873) | (1.5754) | (1.4205) | (1.3137) | (0.0452) | (1.3617) | (1.2276) | (1.14) | 1.2252 | (0.6332) | (0.606) | (0.6223) | (0.801) | (0.84) |
| IOVA | (0.0471) | (33.8419) | (4.1421) | (2.5999) | (0.4817) | (0.6228) | (0.957) | (1.4111) | (1.2704) | (1.5046) | (1.8599) | (2.137) | (2.4484) | (1.8885) | (1.98) |
| TSVT | (8.5775) | (8.5775) | (8.5775) | (8.5775) | (8.5775) | (8.5775) | (8.5775) | (8.5775) | (8.5775) | (13.8848) | (5.9332) | (11.7114) | (7.1315) | (4.4153) | (4.64) |
| PBYI | (0.3841) | (0.5106) | (3.4199) | (1.9047) | (4.7316) | (7.4488) | (8.2895) | (7.8559) | (2.994) | (2.1338) | (1.5161) | (0.7161) | 0.0204 | 0.4581 | 0.48 |
| SRPT | (2.1667) | (0.1073) | (5.14) | (3.31) | (3.3925) | (5.2029) | (5.49) | (0.8618) | (5.4629) | (9.7137) | (7.1082) | (5.1535) | (8.0344) | (5.8007) | (6.09) |
| AVXL | (0.0075) | (1.1789) | (0.4638) | (1.1595) | (0.6515) | (0.4192) | (0.3296) | (0.3908) | (0.5377) | (0.4516) | (0.5431) | (0.6238) | (0.5954) | (0.68) | (0.72) |
| ANVS | (0.1553) | (0.1553) | (0.1553) | (0.1553) | (0.1553) | (0.1553) | (0.1553) | (0.1553) | (0.1623) | (0.066) | (0.6748) | (1.8931) | (3.0807) | (6.229) | (5.92) |
| AXSM | (0.1704) | (0.1704) | (0.1704) | (0.1704) | (0.4718) | (0.884) | (1.4204) | (1.2714) | (1.1518) | (2.0484) | (2.8325) | (3.5871) | (4.8644) | (5.2666) | (5.0) |
| NVAX | (10.8557) | (3.4089) | (4.3282) | (6.128) | (7.3454) | (11.9686) | (20.6768) | (12.5585) | (9.9929) | (5.3984) | (7.4279) | (23.4375) | (8.4154) | (5.4091) | (5.68) |
Veru Inc and related stocks such as Seres Therapeutics, Protalix Biotherapeutics, and Lexicon Pharmaceuticals Net Income Per Share description
My Equities
My Current Equities and Potential Positions
| Veru Inc | VERU |
| Classification | Pharmaceutical Products |
| Location | Florida; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.71
Additional Tools for Veru Stock Analysis
When running Veru's price analysis, check to measure Veru's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veru is operating at the current time. Most of Veru's value examination focuses on studying past and present price action to predict the probability of Veru's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veru's price. Additionally, you may evaluate how the addition of Veru to your portfolios can decrease your overall portfolio volatility.